Trial Profile
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 11 Mar 2024 Planned End Date changed from 1 May 2024 to 1 May 2025.
- 09 Jun 2023 Planned End Date changed from 1 May 2023 to 1 May 2024.
- 07 Jul 2021 Status changed from recruiting to active, no longer recruiting.